Preclinical Discovery
Enter IND and Phase 1 studies with validated targets and mechanistic insights predictive of therapeutic response.
Target Identification
Profile over 1T marker combinations to identify novel targets across the innate and adaptive immune system.
Mechanism of Action
Understand the complex network of immune cell interactions associated with your target.
Target Validation
Select an approach that maximizes therapeutic response to facilitate entry into IND-study.
Target Identification
Don’t limit yourself to a handful of subsets, expand your immune profiling capabilities to identify which aspects of biology your candidate is hitting.
Mechanism of Action
Before Teiko.bio
The assumption is CD8 T cells need to be targeted directly. However, this leads to therapy failure.
With Teiko.bio
Immune profiling reveals the actual issue is upstream, with dendritic cells not being activated.
After Teiko.bio
Upstream anti-CD40 therapy activates dendritic cells to create therapy success.
Target Validation
- Identify approaches that maximize therapeutic effect
- Explore which combination strategies to pursue
- Validate a therapeutic approach and target to enter for IND-stage study
Expertly Designed Mouse Panel
The TokuProfile Mouse Base Panel was constructed based on extensive prior knowledge, input from our collaborative network, and experience over the course of dozens of unique mass cytometry projects. The panel includes:
- Markers to identify every major immune cell population and subsets.
- Expression of key co-stimulatory and co-inhibitory molecules that regulate cell function
- Markers of recent activation and effector function.
- Up to 11 open channels for customization included
Expertly Designed Non-Human Primate Panel
The TokuProfile NHP Base Panel was constructed based on extensive prior knowledge, input from our collaborative network, and experience over the course of multiple mass cytometry projects. The panel includes:
- Markers to identify every major immune cell population and subsets
- Expression of key co-stimulatory and co-inhibitory molecules that regulate cell function
- Markers of recent activation and effector function
- Up to 13 open channels for customization included
-
T cells
- CD3
- Total T cells
- CD4
- CD4+ T cells
- CD8
- CD8+ T cells
- Foxp3
- Tregs
- CD25
- Treg, activation
- CD27
- Maturation
- CD28
- Co-stimulation
- CD127
- T cell subsets
- CCR7
- Naive/Memory cells
- CD45RA
- Naive/Memory cells
- gdTCR
- gdT cells
- CD56
- NKT cells
- CD161
- Th17, iNKT cells
- CD69
- Activation
- HLA-DR
- Activation
- CXCR4
- Homing
- CTLA-4
- Checkpoint
- PD-1
- Checkpoint
- CD39
- Exhaustion, tumor specific
-
B cells
- CD20
- Total B cells
- CD27
- Naive/Memory
- CD25
- Activation
- CD69
- Activation
- HLA-DR
- Antigen presentation
-
NK cells
- CD56
- NK cell subsets
- CD16
- NK cell subsets
- CD8
- NK cell subsets
- NKG2a
- Inhibitory receptor
- CD161
- Cytokine responsiveness
-
Myeloid cells
- CD33
- Total myeloid cells
- CD11b
- Monocytes, Macrophages
- CD11c
- Monocytes, Macrophages, DCs
- CD14
- Monocyte subsets, Macrophages
- CD16
- Monocyte subsets
- CD123
- pDCs
- CD86
- Antigen presentation
- HLA-DR
- Antigen presentation
- PD-L1
- Checkpoint
-
Granulocytes
Whole blood only- CD11b
- Neutrophils
- CD16
- Neutrophils
- CD123
- Basophils
-
General
- CD45
- Total immune cells
- KI-67
- Proliferation
- DNA, Live/Dead
- Viability
-
13 open channels for customization